Pasar al contenido principal

BRUCELLOSIS: TESTS DIAGNOSTICOS Y VACUNAS DIVA FRENTE A BRUCELLA OVIS Y BRUCELLA SUIS

AGL2014-58795-C4-2-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Vaccine properties of Brucella melitensis 16MΔwzm and reactivation of placental infection in pregnant sheep

  • Zabalza-Baranguá, A.
  • Poveda-Urkixo, Irati
  • Mena-Bueno, S.
  • Ramírez, G. A.
  • De Bolle, X.
  • Grilló, M. J.
Brucellosis, a worldwide zoonotic disease, is endemic in many developing countries. Besides causing significant economic losses for the livestock industry, it has severe consequences for human health. In endemic regions, small ruminants infected by Brucella melitensis are the main source of human brucellosis. Rev1, the only vaccine currently recommended to control the disease in sheep and goats, has several drawbacks. Rough lipopolysaccharide (R-LPS) mutants have been tested as alternatives, but most lack efficacy. Those in the Wzm/Wzt system responsible for O-polysaccharide export to the periplasm have been proposed as promising vaccine candidates, although to date they have been scarcely investigated in the natural host. In the present work, we studied the biological properties of a 16MΔwzm in-frame deletion mutant, including its safety in pregnant mice and sheep. In mice, 16MΔwzm prevented placental and fetal infections before parturition and protected against B. melitensis and Brucella ovis infections. In sheep, 16MΔwzm was equally safe in lambs, rams, and non-pregnant ewes, inducing some transient Rose Bengal reactions (<7 weeks). The serological reactions occurred earlier and more strongly in pregnant than in non-pregnant ewes and were significantly reduced when conjunctival rather than subcutaneous vaccination was used. In ewes vaccinated at mid-pregnancy, 16MΔwzm was not shed in vaginal discharges during the pregnancy and did not induce abortions/stillbirths. However, some ewes showed a transitory reactivation of infection in placentas and/or milk at parturition, accompanied by a seroconversion in smooth LPS (S-LPS) and/or R-LPS tests. Overall, 16MΔwzm can be considered as a safe vaccine for lambs, rams, and non-pregnant ewes, but its use at mid-pregnancy should be avoided to prevent vaccine dissemination at parturition. If the efficacy results against B. melitensis and B. ovis observed in mice are confirmed by further studies in the natural host, 16MΔwzm could constitute a useful vaccine., This work was funded by the Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades of Spain (AGL2014-58795-C4-2-R and RTI2018-098658-B-C21) and Dirección General de Industria, Energía Proyectos Estratégicos S3 of Gobierno de Navarra, Spain (projects PT068-2018 and PT007-2019). IPU was contracted in the context of the Doctorados Industriales program of Gobierno de Navarra, co-funded by CSIC (2017-2020). SMB contracts were funded by the “Garantía Juvenil” program of CSIC-FEDER 2016-2018 and a predoctoral (2018-2019) fellowship of the Public University of Navarra (UPNA, Spain). Also, we thank the scientific advice of Professor Jean-Jacques Letesson; and the technical support of Sagrario Pérez, Elena San Miguel and Manuel Barrón (LCA-Navarra, Spain) as well as the staff of the subcontracted companies Maeva Servet-Visavet and Animalia (Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brucella abortus S19 GFP-tagged vaccine allows the serological identification of vaccinated cattle

  • Chacón Diaz, Carlos
  • Zabalza-Baranguá, Ana
  • San Román, Beatriz
  • Blasco, José M.
  • Iriarte, Maite
  • Salas-Alfaro, Dariana
  • Hernández-Mora, Gabriela
  • Barquero-Calvo, Elías
  • Guzmán Verri, Caterina
  • Chaves Olarte, Esteban
  • Grilló, María Jesús
  • Moreno Robles, Eduardo
Bovine brucellosis induces abortion in cows, produces important economic losses, and causes a widely distributed zoonosis. Its eradication was achieved in several countries after sustained vaccination with the live attenuated Brucella abortus S19 vaccine, in combination with the slaughtering of serologically positive animals. S19 induces antibodies against the smooth lipopolysaccharide (S-LPS), making difficult the differentiation of infected from vaccinated bovines. We developed an S19 strain constitutively expressing the green fluorescent protein (S19-GFP) coded in chromosome II. The S19-GFP displays similar biological characteristics and immunogenic and protective efficacies in mice to the parental S19 strain. S19-GFP can be distinguished from S19 and B. abortus field strains by fluorescence and multiplex PCR. Twenty-five heifers were vaccinated withS19-GFP (5×10 CFU) by the subcutaneous or conjunctival routes and some boosted with GFP seven weeks thereafter. Immunized animals were followed up for over three years and tested for anti-S-LPS antibodies by both the Rose Bengal test and a competitive ELISA. Anti-GFP antibodies were detected by an indirect ELISA and Western blotting. In most cases, anti-S-LPS antibodies preceded for several weeks those against GFP. The anti-GFP antibody response was higher in the GFP boosted than in the non-boosted animals. In all cases, the anti-GFP antibodies persisted longer, or at least as long, as those against S-LPS. The drawbacks and potential advantages of using the S19-GFP vaccine for identifying vaccinated animals in infected environments are discussed., This work was partially supported by the FES-CONARE of Costa Rica (www.conare.ac.cr), projects UNA 0009-12, 0248-13, 0504-13, 0505-13 from Universidad Nacional (www.investigacion.una.ac.cr). Grant 803-C0-456, 803-B3-761 Red Temática de brucelosis, Vicerrectoría de Investigación of the University of Costa Rica (www.vinv.ucr.ac.cr). Grant B8762 from Espacio Estudios Avanzados (UCREA) from the University of Costa Rica (www.ucrea.ucr.ac.cr). Bilateral cooperation CSIC-CRUSA Foundation (ref. 2010CR0005)(www.crusa.cr); grants from the Spanish Minister of Economy and Competitiveness (MINECO refs. AGL2010-20247, AGL2011-30453-C04-00, AGL2014-58795-C4-2-R and RTC-2015-3618-1). Fellowship support for The doctoral contract of Ana Zabalza was funded by Public University of Navarra, and the postdoctoral contract of Beatriz San Román was funded by JAE-DOC program of CSIC co-funded by European Social Fund (FSE, European Commission) and MINECO (AGL2011-30453-C04-00) of Spain (www.mineco.gob.es). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brucella melitensis Wzm/Wzt System: Changes in the Bacterial Envelope Lead to Improved Rev1Δwzm Vaccine Properties

  • Mena Bueno, Sara
  • Poveda-Urkixo, Irati
  • Irazoki, Oihane
  • Palacios Chaves, Leyre
  • Cava, Felipe
  • Zabalza-Baranguá, Ana
  • Grilló, María Jesús
The lipopolysaccharide (LPS) O-polysaccharide (O-PS) is the main virulence factor in Brucella. After synthesis in the cytoplasmic membrane, O-PS is exported to the periplasm by the Wzm/Wzt system, where it is assembled into a LPS. This translocation also engages a bactoprenol carrier required for further biosynthesis pathways, such as cell wall biogenesis. Targeting O-PS export by blockage holds great potential for vaccine development, but little is known about the biological implications of each Wzm/Wzt moiety. To improve this knowledge and to elucidate its potential application as a vaccine, we constructed and studied wzm/wzt single- and double-deletion mutants, using the attenuated strain Brucella melitensis Rev1 as the parental strain. This allowed us to describe the composition of Brucella peptidoglycan for the first time. We observed that these mutants lack external O-PS yet trigger changes in genetic transcription and in phenotypic properties associated with the outer membrane and cell wall. The three mutants are highly attenuated; unexpectedly, Rev1Δwzm also excels as an immunogenic and effective vaccine against B. melitensis and Brucella ovis in mice, revealing that low persistence is not at odds with efficacy. Rev1Δwzm is attenuated in BeWo trophoblasts, does not infect mouse placentas, and is safe in pregnant ewes. Overall, these attributes and the minimal serological interference induced in sheep make Rev1Δwzm a highly promising vaccine candidate., This work was funded by Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades (AGL2014-58795-C4-2-R and RTI2018-098658-B-C21), Gobierno de Navarra (PT040-2018 and PT007-2019) projects. SM-B contracts were granted by the FEDER 2016–2018 program of Garantía Juvenil and by an UPNA pre-doctoral fellowship 2018–2022. IP-U Doctorados Industriales contract was cofounded by Gobierno de Navarra and CSIC. Research in the FC lab was supported by The Swedish Research Council (VR), The Knut and Alice Wallenberg Foundation (KAW), The Laboratory of Molecular Infection Medicine Sweden (MIMS), and The Kempe Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

BruSIC: a novel selective medium for the primary isolation of Brucella in veterinary samples

  • Mena-Bueno, Sara
  • Poveda-Urkixo, Irati
  • Asensio, Daniel
  • Echarte, Iñaki
  • Zabalza-Baranguá, Ana
  • Grilló, María Jesús
Brucellosis, a re-emerging zoonotic infection, threatens animal welfare and public health with serious economic consequences. A definitive diagnosis requires Brucella isolation by culturing field specimens in specific media. This study aimed to (i) assess the effectivity of recommended Farrell’s médium (FM) and CITA medium (CM) for the isolation of four Brucella melitensis strains (16M, Rev1, and the 16MDwzm and Rev1Dwzm in-frame deletion mutants) with variable susceptibility to polymyxins; (ii) develop a Brucella selective medium (BSM) suitable for these strains; (iii) test BSM, FM, and CM with other Brucella species; and (iv) develop an improved selective culture medium (BruSIC) for all brucellae, including B. abortus bv1. The four B. melitensis strains were strongly inhibited in FM and (except Rev1) CM. Since Rev1Dwzm’s CM inhibition was due to a synergistic effect of colistin and vancomycin, we formulated BSM with half the concentrations of both antibiotics, achieving a similar growth of B. melitensis to blood agar base (BAB) and an inhibition of contaminant microorganisms comparable to CM; CM performance was surpassed by BSM for the primary isolation of B. melitensis when tested in 1,789 real sheep samples. For other brucellae, BSM and CM were more inhibitory than FM for B. abortus bv1 when using plates immediately after preparation but not after $4 weeks of storage. To address this, we developed the improved solid medium BruSIC by replacing the calf serum in BSM with activated charcoal. BruSIC yielded faster colony growth than BSM and CM and similar CFU numbers than BAB (including for B. ovis in BAB-Serum) and inhibited accompanying microorganisms in sheep and cow samples as effectively as BSM., This study was funded by the Department of Industry of the Gobierno de Navarra (PT068-2018 and PT007-2019) and Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades (AGL2014-58795-C4-2-R and RTI2018-098658-B-C21). The contract of S.M.-B. was granted by a UPNA 2018-2022 predoctoral fellowship, and that of I.P.-U. was granted by the Doctorados Industriales program of the Gobierno de Navarra cofunded by CSIC. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the staff of Laboratorio Central de Sanidad Animal (LCSA; Granada, Spain) for supplying some of the strains, and the staff of VISAVET (UCM, Madrid, Spain) and INTIA (Navarra Government, Spain) for their veterinary assistance and/or support in obtaining animal samples.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vaccine properties of Brucella melitensis 16MΔwzm and reactivation of placental infection in pregnant sheep

  • Zabalza-Baranguá, Ana
  • Poveda-Urkixo, Irati
  • Mena Bueno, Sara
  • Ramírez, Gustavo A.
  • De Bolle, Xavier
  • Grilló, María Jesús
Brucellosis, a worldwide zoonotic disease, is endemic in many developing countries. Besides causing significant economic losses for the livestock industry, it has severe consequences for human health. In endemic regions, small ruminants infected by Brucella melitensis are the main source of human brucellosis. Rev1, the only vaccine currently recommended to control the disease in sheep and goats, has several drawbacks. Rough lipopolysaccharide (R-LPS) mutants have been tested as alternatives, but most lack efficacy. Those in the Wzm/Wzt system responsible for O-polysaccharide export to the periplasm have been proposed as promising vaccine candidates, although to date they have been scarcely investigated in the natural host. In the present work, we studied the biological properties of a 16MΔwzm in-frame deletion mutant, including its safety in pregnant mice and sheep. In mice, 16MΔwzm prevented placental and fetal infections before parturition and protected against B. melitensis and Brucella ovis infections. In sheep, 16MΔwzm was equally safe in lambs, rams, and non-pregnant ewes, inducing some transient Rose Bengal reactions (<7 weeks). The serological reactions occurred earlier and more strongly in pregnant than in non-pregnant ewes and were significantly reduced when conjunctival rather than subcutaneous vaccination was used. In ewes vaccinated at mid-pregnancy, 16MΔwzm was not shed in vaginal discharges during the pregnancy and did not induce abortions/stillbirths. However, some ewes showed a transitory reactivation of infection in placentas and/or milk at parturition, accompanied by a seroconversion in smooth LPS (S-LPS) and/or R-LPS tests. Overall, 16MΔwzm can be considered as a safe vaccine for lambs, rams, and non-pregnant ewes, but its use at mid-pregnancy should be avoided to prevent vaccine dissemination at parturition. If the efficacy results against B. melitensis and B. ovis observed in mice are confirmed by further studies in the natural host, 16MΔwzm could constitute a useful vaccine., This work was funded by the Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades of Spain (AGL2014-58795-C4-2-R and RTI2018-098658-B-C21) and Dirección General de Industria, Energía Proyectos Estratégicos S3 of Gobierno de Navarra, Spain (projects PT068-2018 and PT007-2019). IPU was contracted in the context of the Doctorados Industriales program of Gobierno de Navarra, co-funded by CSIC (2017-2020). SMB contracts were funded by the “Garantía Juvenil” program of CSIC-FEDER 2016-2018 and a predoctoral (2018-2019) fellowship of the Public University of Navarra (UPNA, Spain). Also, we thank the scientific advice of Professor Jean-Jacques Letesson; and the technical support of Sagrario Pérez, Elena San Miguel and Manuel Barrón (LCA-Navarra, Spain) as well as the staff of the subcontracted companies Maeva Servet-Visavet and Animalia (Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Vaccine properties of Brucella melitensis 16MΔwzm and reactivation of placental infection in pregnant sheep

  • Zabalza-Baranguá, A.
  • Poveda-Urkixo, Irati
  • Mena-Bueno, S.
  • Ramírez, G. A.
  • De Bolle, X.
  • Grilló, M. J.
Brucellosis, a worldwide zoonotic disease, is endemic in many developing countries. Besides causing significant economic losses for the livestock industry, it has severe consequences for human health. In endemic regions, small ruminants infected by Brucella melitensis are the main source of human brucellosis. Rev1, the only vaccine currently recommended to control the disease in sheep and goats, has several drawbacks. Rough lipopolysaccharide (R-LPS) mutants have been tested as alternatives, but most lack efficacy. Those in the Wzm/Wzt system responsible for O-polysaccharide export to the periplasm have been proposed as promising vaccine candidates, although to date they have been scarcely investigated in the natural host. In the present work, we studied the biological properties of a 16MΔwzm in-frame deletion mutant, including its safety in pregnant mice and sheep. In mice, 16MΔwzm prevented placental and fetal infections before parturition and protected against B. melitensis and Brucella ovis infections. In sheep, 16MΔwzm was equally safe in lambs, rams, and non-pregnant ewes, inducing some transient Rose Bengal reactions (<7 weeks). The serological reactions occurred earlier and more strongly in pregnant than in non-pregnant ewes and were significantly reduced when conjunctival rather than subcutaneous vaccination was used. In ewes vaccinated at mid-pregnancy, 16MΔwzm was not shed in vaginal discharges during the pregnancy and did not induce abortions/stillbirths. However, some ewes showed a transitory reactivation of infection in placentas and/or milk at parturition, accompanied by a seroconversion in smooth LPS (S-LPS) and/or R-LPS tests. Overall, 16MΔwzm can be considered as a safe vaccine for lambs, rams, and non-pregnant ewes, but its use at mid-pregnancy should be avoided to prevent vaccine dissemination at parturition. If the efficacy results against B. melitensis and B. ovis observed in mice are confirmed by further studies in the natural host, 16MΔwzm could constitute a useful vaccine., This work was funded by the Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades of Spain (AGL2014-58795-C4-2-R and RTI2018-098658-B-C21) and Dirección General de Industria, Energía Proyectos Estratégicos S3 of Gobierno de Navarra, Spain (projects PT068-2018 and PT007-2019). IPU was contracted in the context of the Doctorados Industriales program of Gobierno de Navarra, co-funded by CSIC (2017-2020). SMB contracts were funded by the “Garantía Juvenil” program of CSIC-FEDER 2016-2018 and a predoctoral (2018-2019) fellowship of the Public University of Navarra (UPNA, Spain). Also, we thank the scientific advice of Professor Jean-Jacques Letesson; and the technical support of Sagrario Pérez, Elena San Miguel and Manuel Barrón (LCA-Navarra, Spain) as well as the staff of the subcontracted companies Maeva Servet-Visavet and Animalia (Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Brucella melitensis wzm/wzt system: changes in the bacterial envelope lead to improved rev1Δwzm vaccine properties

  • Mena Bueno, Sara
  • Poveda Urkixo, Irati
  • Irazoki, Oihane
  • Palacios Chaves, Leyre
  • Cava, Felipe
  • Zabalza Baranguá, Ana
  • Grilló Dolset, María Jesús
The lipopolysaccharide (LPS) O-polysaccharide (O-PS) is the main virulence factor in Brucella. After synthesis in the cytoplasmic membrane, O-PS is exported to the periplasm by the Wzm/Wzt system, where it is assembled into a LPS. This translocation also engages a bactoprenol carrier required for further biosynthesis pathways, such as cell wall biogenesis. Targeting O-PS export by blockage holds great potential for vaccine development, but little is known about the biological implications of each Wzm/Wzt moiety. To improve this knowledge and to elucidate its potential application as a vaccine, we constructed and studied wzm/wzt single- and double-deletion mutants, using the attenuated strain Brucella melitensis Rev1 as the parental strain. This allowed us to describe the composition of Brucella peptidoglycan for the first time. We observed that these mutants lack external O-PS yet trigger changes in genetic transcription and in phenotypic properties associated with the outer membrane and cell wall. The three mutants are highly attenuated; unexpectedly, Rev1Δwzm also excels as an immunogenic and effective vaccine against B. melitensis and Brucella ovis in mice, revealing that low persistence is not at odds with efficacy. Rev1Δwzm is attenuated in BeWo trophoblasts, does not infect mouse placentas, and is safe in pregnant ewes. Overall, these attributes and the minimal serological interference induced in sheep make Rev1Δwzm a highly promising vaccine candidate., This work was funded by Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades (AGL2014-58795-C4-2-R and RTI2018-098658-B-C21), Gobierno de Navarra (PT040-2018 and PT007-2019) projects. SM-B contracts were granted by the FEDER 2016–2018 program of Garantía Juvenil and by an UPNA pre-doctoral fellowship 2018–2022. IP-U Doctorados Industriales contract was cofounded by Gobierno de Navarra and CSIC. Research in the FC lab was supported by The Swedish Research Council (VR), The Knut and Alice Wallenberg Foundation (KAW), The Laboratory of Molecular Infection Medicine Sweden (MIMS), and The Kempe Foundation.